Is the increase in eltrombopag dose cause of myocardial infarction?

Özgünoğlu, Edip Can; Bayar, Nermin; Arslan, Şakir; Ersoysal, Muhammed Rıdvan; Avcı, Rauf

Journal Metrics

Impact Factor (2022): 1.3
5-Year Impact Factor: 1.5
Eigenfactor Score: 0.00148
CiteScore (2022): 1.9
SCImago Journal Rank: 0.29

27/12Current Issue Ahead of Print Archive Most Accessed Articles

Quick Search

In authors and institutes
In titles and abstracts
In keywords
In all

pdf

Is the increase in eltrombopag dose cause of myocardial infarction? [Anatol J Cardiol]

Anatol J Cardiol. 2021; 25(7): 520-521 | DOI: 10.5152/AnatolJCardiol.2021.45605

Is the increase in eltrombopag dose cause of myocardial infarction?

Edip Can Özgünoğlu, Nermin Bayar, Şakir Arslan, Muhammed Rıdvan Ersoysal, Rauf Avcı
Department of Cardiology, University of Health Sciences, Antalya Training and Research Hospital; Antalya-Turkey

Keywords: myocard infarction, eltrombopag, ITP, Gp2b/3a

Eltrombopag doz artışı miyokard infarktüsü nedeni olabilir mi?

Edip Can Özgünoğlu, Nermin Bayar, Şakir Arslan, Muhammed Rıdvan Ersoysal, Rauf Avcı
Sağlık Bilimleri Üniversitesi Antalya Eğitim Ve Araştırma Hastanesi, Kardiyoloji Kliniği, Antalya

Anahtar Kelimeler: miyokard infarktüsü, eltrombopag, ITP, Gp2b/3a

Edip Can Özgünoğlu, Nermin Bayar, Şakir Arslan, Muhammed Rıdvan Ersoysal, Rauf Avcı. Is the increase in eltrombopag dose cause of myocardial infarction?. Anatol J Cardiol. 2021; 25(7): 520-521

Corresponding Author: Edip Can Özgünoğlu, Türkiye
Manuscript Language: English

TOOLS Full Text PDF Print Download citation RIS EndNote BibTex Medlars Procite Reference Manager Share with email Share Send email to author Similar articles PubMed Google Scholar

Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper: 0.22
SCImago Journal Rank: 0.348

Quick Search

In authors and institutes
In titles and abstracts
In keywords
In all